Serum oxLDL-β2GPI complex reflects metabolic syndrome and inflammation in adipose tissue in obese
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
29081508
DOI
10.1038/ijo.2017.260
PII: ijo2017260
Knihovny.cz E-zdroje
- MeSH
- beta-2-glykoprotein I krev chemie metabolismus MeSH
- biologické markery krev MeSH
- dospělí MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lipoproteiny LDL krev chemie metabolismus MeSH
- metabolický syndrom krev patofyziologie MeSH
- multiproteinové komplexy MeSH
- obezita * krev metabolismus patofyziologie MeSH
- tuková tkáň metabolismus patofyziologie MeSH
- zánět krev patofyziologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- beta-2-glykoprotein I MeSH
- biologické markery MeSH
- lipoproteiny LDL MeSH
- multiproteinové komplexy MeSH
- oxidized low density lipoprotein MeSH Prohlížeč
BACKGROUND/OBJECTIVES: OxLDL-β2GPI complex has been suggested to have a role in the development of atherosclerosis and other inflammatory diseases. The aim of this study was to investigate the possible association of circulating oxLDL-β2GPI with obesity-induced inflammatory state of adipose tissue and related comorbidities as metabolic syndrome development. SUBJECTS/METHODS: Two cohorts of subjects were examined in the study. Cohort I: 36 women with wide range of body mass index (17-48 kg m-2) and metabolic status (with or without metabolic syndrome (MS); cohort II: 20 obese women undergoing a dietary intervention (DI) consisting of 1-month very-low-calorie diet, and 5 months of weight-stabilization period. Serum levels of oxLDL-β2GPI were measured by enzyme-linked immunosorbent assay. Insulin sensitivity was evaluated by hyperinsulinemic-euglycemic clamp and homeostasis model assessment of insulin resistance. mRNA expression of macrophage markers was determined in both subcutaneous (SAT) and visceral (VAT) adipose tissue in cohort I and in SAT in cohort II. RESULTS: Serum oxLDL-β2GPI levels were increased in obese subjects with MS compared to lean or obese without MS (obese with MS: 26.6±5.0 vs lean: 15.17±1.97, P<0.001; vs obese without MS: 16.36±2.89, P<0.05). Serum oxLDL-β2GPI correlated with MS indices (glucose, high-density lipoprotein, triglyceride and ureic acid) and with mRNA expression of macrophage markers in VAT. Weight-reducing DI decreased serum oxLDL-β2GPI levels together with lipid parameters and the mRNA expression of inflammatory markers in SAT. CONCLUSIONS: OxLDL-β2GPI seems to be an important marker of visceral adipose tissue inflammation and possibly a factor contributing to insulin resistance and metabolic syndrome development in obese patients.
Zobrazit více v PubMed
Diabetes. 2009 Jul;58(7):1558-67 PubMed
Diabetes Res Clin Pract. 2014 Aug;105(2):141-50 PubMed
J Transl Med. 2016 Jul 11;14 (1):208 PubMed
Lancet. 1998 May 2;351(9112):1301-2 PubMed
Semin Dial. 2006 Jan-Feb;19(1):32-40 PubMed
Cardiovasc Diabetol. 2013 Aug 05;12:112 PubMed
J Clin Endocrinol Metab. 2010 Jun;95(6):2845-50 PubMed
Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11527-31 PubMed
Obesity (Silver Spring). 2013 Jan;21(1):E71-7 PubMed
Ann Nutr Metab. 2013;62(1):7-13 PubMed
Clin Exp Immunol. 1997 Mar;107(3):569-73 PubMed
Ann N Y Acad Sci. 2001 Dec;947:214-22; discussion 222-3 PubMed
Atherosclerosis. 2015 Jul;241(1):176-82 PubMed
Circulation. 1999 May 4;99(17):2227-30 PubMed
Free Radic Biol Med. 1997;22(6):1115-26 PubMed
Autoimmun Rev. 2002 Aug;1(4):233-7 PubMed
Int J Mol Med. 2014 May;33(5):1341-7 PubMed
Diabetes. 2013 Jun;62(6):1990-5 PubMed
Annu Rev Biochem. 2017 Jun 20;86:715-748 PubMed
Atherosclerosis. 1991 Oct;90(2-3):119-26 PubMed
Lipids Health Dis. 2016 Aug 20;15:133 PubMed
Autoimmun Rev. 2012 Dec;12(2):241-9 PubMed
Int J Obes (Lond). 2011 Jan;35(1):91-8 PubMed
Lancet. 2005 Sep 24-30;366(9491):1059-62 PubMed
Metabolism. 1987 Jan;36(1):54-9 PubMed
Cell Metab. 2014 Jan 7;19(1):162-171 PubMed
Nat Med. 2012 Mar 06;18(3):363-74 PubMed
Ann N Y Acad Sci. 2005 Jun;1051:97-103 PubMed
J Immunol Res. 2014;2014:234316 PubMed
J Autoimmun. 2007 Sep-Nov;29(2-3):164-73 PubMed
Curr Pharm Des. 2016;22(24):3715-29 PubMed
J Atheroscler Thromb. 2014;21(11):1140-51 PubMed
Curr Diab Rep. 2006 Jun;6(3):177-81 PubMed
Blood. 2005 Feb 15;105(4):1552-7 PubMed
Ann N Y Acad Sci. 2005 Jun;1051:313-22 PubMed
Am J Physiol. 1979 Sep;237(3):E214-23 PubMed
Eur J Clin Invest. 2016 Jun;46(6):520-6 PubMed
Int J Obes (Lond). 2017 May;41(5):672-682 PubMed
Am J Clin Pathol. 2010 May;133(5):737-43 PubMed
Diabetes. 2000 Jun;49(6):883-8 PubMed
J Am Coll Cardiol. 2006 Jun 20;47(12):2436-43 PubMed
Acta Diabetol. 2014 Feb;51(1):123-31 PubMed
Arterioscler Thromb Vasc Biol. 2001 May;21(5):844-8 PubMed
Diabetologia. 2011 Apr;54(4):876-87 PubMed
